Global Cell Therapy Biomanufacturing Market (2020 to 2025) - Featuring Lonza Group, Merck & Novartis Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Cell Therapy Biomanufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering.

This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region. The report discusses the key inhibitors to the growth of cell therapy biomanufacturing. The report discusses the role of participants in the supply chain from manufacturers to researchers. The report analyzes key companies operating in the global cell therapy biomanufacturing market. In-depth patent analysis in the report will provide a look at the existing and coming technological trends.

In this report, the cell therapy biomanufacturing market is segmented by product type, application and region. Based on product type, the market is segmented into source of cells (T-cells, Dendritic cells, tumor cells and stem cells), and type of therapy (autologous cell therapies, allogeneic cell therapies). The market by application is categorized into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair, cancer and others. The market by region is segmented into North America, Europe, Asia-Pacific and ROW.

An increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, and further development of stem cell therapy approaches are driving the market's growth. However, market restraints include the bottlenecks experienced by manufacturers during commercialization of cell therapies and the high costs associated with cell therapies. The rise in the development of allogeneic cell therapy is expected to drive the market's growth. Allogeneic cell therapy involves chemo radiotherapeutic conditioning therapy that is followed by transplantation of hematopoietic stem cells as well as lymphocytes isolated from allogeneic healthy donors for treatment of various chronic diseases. (Allogeneic means from "one person to another," vs. autologous, which means from "one person back to the same person after processing.")

Companies Mentioned

  • Bone Therapeutics Sa
  • Bristol-Myers Squibb Co.
  • Caladrius Biosciences Inc.
  • Cell Therapies Pty Ltd.
  • Cellular Biomedicine Group Inc.
  • Iovance Biotherapeutics Inc.
  • Lonza Group Ltd.
  • Merck Kgaa
  • Neurogeneration Inc.
  • Novartis Ag
  • Regen Biopharma Inc.
  • Regeneus Ltd.

Report Includes:

  • 23 tables
  • An overview of the global markets for cell therapy biomanufacturing
  • Estimation of the market size and analyses of global market trends with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Assessment of market dynamics such as drivers, restraints, opportunities, and identification of growth inhibiting areas that affect the global market
  • Detailed description of allogeneic (third party donor cells) and autologous (one's own body cells) forms of cell therapy and analysis of its advantages and limitations
  • Information on clinical trials of cell therapies; insights into regulatory scenarios and initiatives by government organization
  • Evaluation of current market trends, market size, market forecast, and technological advancements within the industry
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies; and a relevant patent analysis

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

  • Introduction

Chapter 3 Market and Technology Background

  • Introduction to Cell Therapy Biomanufacturing
  • What is Cell Therapy?
  • Stem Cell Transplantation
  • Autologous
  • Allogeneic
  • Syngeneic
  • Stem Cell Biomanufacturing and Classification
  • Based on Ability to Differentiate
  • Based on Source
  • Classification of Cell-Based Therapy Technology
  • Somatic Cell Technologies
  • Three-Dimensional Technologies
  • Cell Immortalization Technologies
  • Genome Editing Technologies
  • Cell Plasticity Technologies
  • Ex vivo Gene Modification of Cells Using Viral Vector Technologies
  • In vivo Gene Modification of Cells Using Viral Vector Technologies
  • Stem Cell Applications
  • Mechanism of Cell Therapy
  • Delivery Method of Cell-Based Therapy
  • Manufacturing Cell Therapy Models
  • Role of Contract Manufacturers
  • Ongoing Clinical Trials
  • Clinical Trial Network Focused on Stem Cell Treatments

Chapter 4 Market Trends and Challenges

  • Challenges
  • Drivers
  • Restraints
  • Opportunity

Chapter 5 Market Breakdown by Product Type

  • Type of Therapy
  • Source of Cells
  • Rise in the Demand for Chimeric Antigen Receptor (CAR) T Cell Therapy

Chapter 6 Market Breakdown by Application

  • Cardiovascular Disease
  • Microparticles Cell Imitation
  • Bone Repair
  • Neurological Disorders
  • Spinal Cord Injury
  • Stroke
  • Parkinson's Disease
  • Amyotrophic Lateral Sclerosis
  • Multiple Sclerosis
  • Cerebral Palsy
  • Alzheimer's Disease
  • Vision Restoration
  • Vertebral Repair
  • Batten's Disease
  • Skeletal Muscle Repair
  • Intrinsic Healing Mechanisms
  • Cell Therapy Mechanism
  • Cancer
  • Other Diseases

Chapter 7 Market Breakdown by Region

  • Market Overview
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Cardiovascular Diseases in Europe
  • Contributing Factors for Cardiovascular Diseases (CVD)
  • Germany
  • U.K.
  • France
  • Asia-Pacific
  • China
  • India
  • Japan
  • Rest of APAC
  • Rest of the World
  • South America
  • Middle East and Africa

Chapter 8 Regulatory Structure

  • FDA Approvals
  • Cell Therapy for CBER Regulations
  • Federal Regulation codes
  • Collection of Cells
  • Code of Regulation
  • Legislation Governing Use of Stem Cell Treatments
  • EU Determination of Regulatory Status
  • Regulatory Scenario in India

Chapter 9 Company Profiles

Chapter 10 Appendix: References

For more information about this report visit https://www.researchandmarkets.com/r/747t6w

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900